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Introduction: The aim of present study is to inverstigate the association between antibody levels after vaccination
with 7-valent pneumococcal conjugate vaccine (PCV7) and subsequent serious pneumococcal infections in rheumatoid
arthritis (RA) and spondylarthropathy (SpA) patients.
Methods: A cohort of 497 patients (RA = 248 and SpA = 249) received a single dose of PCV7. At vaccination,
patients were treated with methotrexate (MTX; n = 85), anti-tumour necrosis factor (anti-TNF) + MTX (n = 169),
anti-TNF monotherapy (n = 158) and non-steroidal anti-inflammatory drugs (NSAIDs)/analgesics (n = 85). Antibody
levels of serotypes 6B and 23B were analyzed before and 4 to 6 weeks after vaccination using standard enzyme-linked
immunosorbent assay (ELISA). Serious pneumococcal infections (pneumonia/lower respiratory tract infection,
meningitis, sepsis, septic arthritis) occurring within 4.5 years after vaccination were identified in the Skåne Healthcare
Register using the International Classification of Diseases, tenth revision (ICD-10) codes. The association between
post-vaccination antibody levels and protection against infections and determination of protective cutoff levels was
explored using receiver operating characteristic (ROC) curves. Predictors of infection were studied using regression analyses.
Results: Eighteen infections were registered in 15 patients before vaccination and 27 infections in 23 patients after
vaccination. Patients with serious infections after vaccination had significantly lower post-vaccination antibody titres for
both 6B (P = 0.04) and 23 F (P = 0.04). Post-vaccination antibody levels of at least 1.29 mg/L and 1.01 mg/L for 6B and
23, respectively, were associated with better protection from serious infections. Higher age, concomitant prednisolone
but not MTX or anti-TNF were associated with such infections.
Conclusions: Patients with more robust antibody responses after vaccination with pneumococcal conjugate vaccine
were less likely to suffer from serious infections. High age and prednisolone at vaccination were associated with
putative serious pneumococcal infections in this cohort.
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Vaccination is an appealing strategy when attempting
to reduce the major global public health problem of
pneumococcal disease [1,2]. Two pneumococcal vaccines
are currently in clinical use. One of them contains 23 cap-
sular polysaccharides (PPV) that primarily induce a B cell-
dependent immune response. This type of vaccine pre-
vents bacteraemia but does not efficiently protect the host
against pneumococcal infection [3,4]. In 2000, a novel
pneumococcal conjugate vaccine (PCV) was launched
containing capsular polysaccharides derived from the
seven most frequent pneumococcal serotypes causing
pneumococcal disease in children <2 years of age. Conju-
gation of capsular polysaccharides with a highly immu-
nogenic protein, that is a non-toxic diphtheria toxoid,
induces a B and T cell response [5] resulting in mucosal
immunity and thus effectively protects against vaccine se-
rotypes that induce invasive pneumococcal disease,
thereby at the same time reducing vaccine serotype carrier
rates [6,7]. Pronounced herd immunity resulted in a de-
crease in invasive pneumococcal diseases in vaccinees and
non-vaccinees as well as reduced antibiotic resistance
rates. However, recent studies report that serotypes eradi-
cated by the vaccine are being replaced by non-vaccine
pneumococcal serotypes. This so-called ‘replacement’
might soon threaten the success of vaccine use [8].
Heptavalent pneumococcal conjugate vaccine has been
shown to prevent recurrent pneumococcal infections in
HIV-infected adults [9]. In a recent report from a
randomised placebo-controlled trial, effectiveness of
the 13-valent pneumococcal conjugate vaccine against
community-acquired pneumonia in adults 65 years and
older was shown [10]. Subsequently, the PCV has been
approved for the immunisation of adults. Since 2012,
the Centers for Disease Control and Prevention (CDC)
Advisory Committee on Immunization Practice (ACIP)
recommends immunisation with a single dose of 13-
valent pneumococcal conjugate vaccine followed by a
dose of PPV to all adults with immunocompromised
conditions [11]. The 2014 updated recommendations
include use of both vaccines to all adults ≥65 years of
age [12].
The majority of patients with inflammatory arthritis
such as rheumatoid arthritis (RA) or spondylarthropathy
(SpA) (including ankylosing spondylitis, psoriatic arthritis
or other spondylarthropathies) are commonly treated with
immunosuppressive remedies and should, according to
ACIPs recommendations, be immunised with pneumo-
coccal conjugate vaccine. However, studies showing that
the vaccine is efficacious in preventing disease caused by
serotypes included in the vaccine in these patients are
scarce [10,13].
Awaiting such studies on antibody response following
vaccination is commonly used as a surrogate measure ofvaccine efficacy. In the Finnish study on polysaccharide
vaccine against Haemophilus influenzae type b (Hib), the
efficacy of the vaccine was found to correlate with post-
vaccination antibody levels of 1 mg/L [14]. Based on the
protective response to Hib vaccine in children, antibody
levels of ≥1 mg/L were estimated to be required for the
long-term protection against encapsulated bacteria in-
cluding pneumococci [14-17]. Among adults no such
levels have been identified. Instead, it has been assumed
that similar antibody concentrations are protective in
adults as well. Given the variability of the various assays
used by most of the major reference laboratories, it is
reasonable to assume that long-term protection probably
does result from a one-month post-vaccine concentra-
tion of between 1 and 1.5 mg/L [17]. However, which
antibody levels would protect against infections may dif-
fer depending on subjects’ age, previous vaccination sta-
tus, other medical conditions and/or concomitant
immunosuppressive treatment [16].
After immunisation with pneumococcal conjugate vac-
cine in children protection was seen at lower post-
vaccination antibody concentrations and antibody levels
≥0.35 mg/L were estimated to be associated with good
protection against infections [18,19]. Studies investigat-
ing the associations between pre- and post-vaccination
antibody levels and protection against infections after
immunisation with pneumococcal conjugate vaccine in
adult patients and with arthritis are lacking.
The aim of the present study was to explore the asso-
ciation between antibody levels before and after vaccin-
ation and the occurrence of pneumococcal infections up
to 4.5 years before and after vaccination with 7-valent
pneumococcal conjugate vaccine (PCV7) in patients
with RA and SpA. In addition, the objective was to iden-
tify the antibody levels (cutoffs) associated with protec-
tion against putative severe pneumococcal infections.
Finally, we wanted to study possible predictors of serious
infections occurring after vaccination.
Methods
Patients
Adult patients with RA and SpA, including psoriatic
arthritis, regularly followed at the outpatient rheumatol-
ogy clinic, Skåne University Hospital in Lund and
Malmö, Sweden were approached consecutively and in-
vited to participate in the study as previously reported
[20]. Eligibility criteria included no previous pneumococ-
cal vaccination or vaccination with 23-valent pneumo-
coccal polysaccharide vaccine ≥5 years before the study
entry. Initially, 505 arthritis patients were enrolled. All
participants were immunised with a single dose of 0.5
ml of PCV7 intramuscularly. Inclusion of patients and
vaccination was performed over a time period of ap-
proximately 1 year (between May 2008 and June 2009).
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ceived from the Regional Ethical Review Board in Lund,
Sweden. Informed consent was obtained from all pa-
tients before inclusion in the study.
Antibody levels for two pneumococcal capsular poly-
saccharide antigens (6B and 23F) were measured before
and 4 to 6 weeks after vaccination using enzyme-linked
immunosorbent assay (ELISA) as previously reported
[21]. The Skåne Healthcare Register (SHR) containing
data on all in- and outpatient care in the region was
used to search for serious pneumococcal infections using
the International Classification of Diseases, tenth revi-
sion (ICD-10) coding system. All such events occurring
between 31 December 2004 and 31 December 2012 were
retrieved [13].
The following infections were included: pneumonia
(J13.9, J18.0, J18.1, J18.9), lower respiratory tract infec-
tion (J22.9), septicaemia (A40.3), meningitis (G00.1)
and septic arthritis (M002B, M002C, M002D, M002F,
M002G, M002H, M002X, M00.1).
In order to reduce the risk of double documentation,
we ignored all repeat codes within the same patient
within 3 months from the first occurrence of the code.
We performed validation of the diagnostic codes by
scrutinising medical records of the patients identified
with serious infections. A positive X-ray or blood cul-
ture, or a C-reactive protein ≥50 was defined as a con-
firmed event.
Of 505 initially immunised patients in total 497 pa-
tients (RA = 248 and SpA = 249) were included in the
present study. The remaining eight patients were ex-
cluded due to moving from the Skåne region. All pa-
tients were divided into predefined treatment groups as
previously described [20].
Statistics
Pre-vaccination and post-vaccination geometric mean
antibody levels (GML) for each serotype were calculated
for patients with a history of serious infections and those
without such infections separately. The Wilcoxon rank
test was used to calculate the differences between post-
and pre-vaccination antibody levels in patients with and
without a history of serious infections, respectively. Differ-
ences in post-vaccination antibody levels between patients
with and without serious infections were calculated using
the Mann-Whitney U test. The impact of age, treatment
and diagnosis on occurrence of serious infections after
vaccination was analysed using a time-dependent Cox re-
gression model and also binary logistic regression analysis.
The association between post-vaccination antibody levels
and infection after vaccination was explored using receiver
operating characteristic (ROC) curves for each serotype
separately. Youden’s index (J statistics) was calculated for
all points of the ROC curves (J = specificity + sensitivity-1)and used as a criterion for selecting optimal cutoff level
[22]. Antibody concentrations associated with protection
against subsequent infections with high specificity and suf-
ficient sensitivity were determined as cutoff levels. A two-
tailed P value less than 0.05 was considered statistically
significant.
Results
Demographics, disease and treatment characteristics of
the RA patients, the SpA patients and the study popula-
tion as a whole, are summarised in Table 1. Patients with
RA were in general older and the majority of these pa-
tients were women (81% versus 45% of SpA patients). At
vaccination, 69% of RA patients and 33% of SpA were
treated with methotrexate (MTX). In total, 34% SpA pa-
tients were on non-steroidal anti-inflammatory drugs
(NSAIDs) only, while no RA patient received these rem-
edies without MTX or tumour necrosis factor (TNF)-in-
hibitors. Approximately one-third of all patients were
treated with anti-TNF +MTX and anti-TNF as mono-
therapy, respectively. The proportion of patients receiv-
ing biologic treatment did not differ between RA and
SpA.
In total, 83% of the infections before and 89% of the
infections after vaccination could be confirmed in the
medical records. Only one patient with a history of ser-
ious infections before vaccination (one RA patient with
three episodes of pneumonia) was recorded for one add-
itional serious infection after vaccination (pneumonia).
Before vaccination
Eighteen serious infections occurred in 15 patients be-
tween 31 December 2004 and May 2008 (one patient
had two and one additional patient had three infections),
Table 1. Out of these 18 infections, 13 occurred among
patients with RA and five among patients with SpA (of
which two were in SpA patients on NSAIDs without
disease-modifying anti-rheumatic drugs (DMARDs)).
The patients with a history of infections before vaccin-
ation had numerically but not statistically lower pre-
vaccination antibody levels. Antibody levels increased
significantly for both serotypes after vaccination among
patients with, as well as without, infections before vac-
cination. (P <0.001 to 0.005 for 6B and P <0.001 to 0.01
for 23F).
After vaccination
During the 4.5 years after vaccination, that is between
May 2008 and 31 December 2012, 27 serious infections
were identified in 23 patients (four patients had two
infections), Table 1. Out of these 27 infections, 23
occurred in RA patients and four in SpA patients (of
which only one in SpA patients on NSAIDs without
DMARDs). One patient with three serious infections
Table 1 Demographic, disease and treatment characteristics of the study population
All patients (n = 497) RA patients (n = 248) SpA patients (n = 249)
Age, mean (SD) (range) years 55.7 (13.0) (22–86) 60.8 (12.4) (24–86) 50.6 (11.6) (22–76)
Sex (% women) 62.8 81.0 44.6
Smoking at vaccination (%) 17.4 19.0 15.7
Disease duration mean (SD) (range) years 14.9 (11.2) (0–48) 15.9 (11.5) (0–48) 13.8 (10.8) (0–45)
DAS28 (SD) (range) 3.2 (1.2) (0–6.4) 3.6 (1.1) (0.6-5.9) 2.8 (1.2) (0–6.4)
DAS28 CRP at vaccination (0–10) 2.7 (0.97) (0.96-5.6) 2.9 (0.9) (0.96-4.9) 2.5 (0.98) (0.96-5.6)
HAQ at vaccination (0–3) (range) 0.7 (0.6) (0–3.0) 0.9 (0.7) (0–3.0) 0.5 (0.5) (0–2.13)
RF at vaccination (%) —— 79.8 ——
Anti-CCP at vaccination (%) —— 77.8 ——
HLA-B27 (%) —— —— 47.8
MTX at vaccination (%) 51.1 69.4 33.0
MTX + anti-TNF at vaccination (%) 31.8 35.1 32.9
Anti-TNF as monotherapy (%) 34.0 30.6 32.9
NSAIDs without other anti-rheumatic treatment (%) 17.1 0 34.1
Serious infection before vaccination (number of events) 18 13 5
Serious infection after vaccination (number of events) 27 23 4
RA, rheumatoid arthritis; SpA, spondylarthropathy; DAS28, disease activity score using 28 joint counts; CRP, C-reactive protein; HAQ, health assessment questionnaire; RF,
rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; HLA-B27, human leukocyte antigen B27; MTX, methotrexate; anti-TNF, anti-tumor necrosis factor; NSAIDs,
non-steroidal anti-inflammatory drugs.
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recurrent infection after vaccination (pneumonia). An-
other patient with two serious infections before vaccin-
ation did not experience additional infections after
vaccination. No other patients with a history of infec-
tions before vaccination had any serious infection after
vaccination.
The patients with a history of serious infections after
vaccination had lower pre-vaccination antibody levels
for serotype 6B (P = 0.07) and 23F (P = 0.03) and lower
post-vaccination antibody levels for both serotypes (P =
0.04 and P = 0.038 for 6B and 23F, respectively; Mann-
Whitney U test), Table 2.
Cutoff levels
A post-vaccination antibody level of 1.29 mg/L for sero-
type 6B was identified as the most optimal cutoff level
(75% specificity and 39% sensitivity; Figure 1). The cor-
responding cutoff levels for serotype 23F was 1.01 mg/L
(73% specificity and 35% sensitivity; Figure 2) [22].
Table 3 shows in boldface the chosen cutoff levels for
both serotypes. The cutoff for 6B could have been
chosen at an antibody level of about 0.70 mg/L, since
that is where the ROC curve indicates a deviation from
the random of 45○, favouring the beginning of protec-
tion against infections, but the sensitivity was as low as
26%. For 23F, the beginning of deviation from the ran-
dom of 45○ coincided more closely with acceptable sen-
sitivity levels at antibody levels of about 1.01 mg/L.Predictors of serious infections
Table 4 summarises results of uni- and multivariate re-
gression analysis using Cox regression model with re-
gard to time between vaccination and occurrence of
infection. Patients with serious infections after vaccin-
ation were older and they suffered more often from RA
than SpA, but the 28 swollen and tender joint count, 66/
68 swollen and tender joint count, disease activity score
using 28 joint counts (DAS28) C-reactive protein (CRP)
or health assessment questionnaire (HAQ) at vaccin-
ation did not differ between patients with or without
such infections.
Patients with serious infections after vaccination re-
ceived oral prednisolone to a larger extent. Mean daily
prednisolone dose (range) in patients with and without
history of serious infection was 3.8 (0 to 10) mg and 1.1
(0 to 20) mg, respectively. The majority of patients with
serious infections were on higher prednisolone doses
(fourth quartile that is ≥7.5 mg daily). Ongoing MTX,
anti-TNF or combination of these treatments at vaccin-
ation were not associated with serious infections after
vaccination, and there were no significant differences in
disease duration at vaccination or between men and
women. Smokers had numerically more infections but
the difference was not significant.
When multivariate analysis was applied higher age
remained a significant predictor of serious infections
while differences between RA and SpA became border-
line significant (P = 0.064). Prednisolone treatment at
Table 2 Geometric mean levels (GML) of pre- and post-
vaccination antibody levels in patients with and without
a history of serious infections after vaccination in all
patients, and RA and SpA patients respectively




N = 470 N = 27
Antibody levels (mg/L) Antibody levels (mg/L)
GML; 95% CI GML; 95% CI
Serotype 6B
Pre-vaccination 1.8 (1.6-2.1) 1.1 (0.6-1.9)
Post-vaccination 4.1 (3.5-4.8) 2.2 (1.3-3.8)
Serotype 23 F
Pre-vaccination 0.8 (0.7-0.9) 0.4 (0.2-0.7)
Post-vaccination 2.6 (2.2-3.0) 1.5 (0.9-2.3)





Pre-vaccination 1.7 (1.4-2.1) 1.0 (0.5-1.8)
Post-vaccination 3.1 (2.5-3.9) 2.0 ( 1.1-3.7)
Serotype 23 F
Pre-vaccination 0.7 (0.6-0.8) 0.3 (0.2-0.7)
Post-vaccination 1.8 (1.4-2.1) 1.4 (0.8-2.4)





Pre-vaccination 1.9 (1.6-2.4) 2.2 (0.5-9.8)
Post-vaccination 5.2 (4.1-6.5) 3.6 (0.7-17.4)
Serotype 23 F
Pre-vaccination 0.8 (0.7-1.0) 0.7 (0.2-2.3)
Post-vaccination 3.6 (3.0-4.5) 1.9 (0.5-6.9)
CI, confidence interval; RA, rheumatoid arthritis; SpA, spondylarthropathy.
Figure 1 Receiver operating characteristic curve shows the association
between post-vaccination antibody concentrations for serotype 6B and
severe infections after vaccination. The rectangle indicates specificity
and sensitivity levels chosen for determination of cutoff.
Figure 2 Receiver operating characteristic curve shows the
association between post-vaccination antibody concentrations for
serotype 23F and severe infections after vaccination. The rectangle
indicates specificity and sensitivity levels chosen for determination
of cutoff.
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predictor of serious infections after adjustment for age
(P <0.001) as well as higher prednisolone doses (P <0.001).
After adjustment for age, neither MTX, biological treat-
ment nor combination of these at vaccination predicted
serious infections. The limited number of events (that is
infections) precluded adjustment for other disease or
treatment characteristics. Similar figures were found when
using an adjusted binary logistic regression model.
Discussion
In the present study, we report the association between
post-vaccination levels of antibodies to pneumococcal cap-
sular polysaccharides and protection against subsequent
putative serious pneumococcal infections. Moreover, we
identified suggestive post-vaccination cutoff antibody
levels associated with the most optimal combination of
Table 3 Different post-vaccination concentrations for
serotype 6B and 23F (cutoffs), corresponding specificity
and sensitivity and predictive values in relation to
occurrence of serious infections after vaccination identified









value % (95% CI)
0.20 95.1 0 0.0 (0–80.7)
0.44 90.3 4.35 2.1 (0.4-11.3)
0.69 85.1 26.1 7.8 (2.9-16.2)
1.02 79.1 30.4 7.0 (2.9-13.9)
1.29 75.1 39.1 7.0 (3.3-12.9)
1.31 74.9 39.1 7.1 (3.3-13.0)
1.45 73.0 39.1 6.6 (3.1-12.2)
1.51 72.4 43.5 6.4 (3.0-11.9)









value % (95% CI)
0.18 95.1 8.7 0.0 (0–17.8)
0.46 85.0 17.4 5.6 (1.8-13.6)
0.71 80.0 21.7 4.9 (1.6-11.0)
0.88 75.3 26.1 5.2 (1.9-10.9)
1.01 73.0 34.8 5.9 (2.6-11.3)
1.10 71.3 34.8 5.6 (2.4-10.7)
1.11 71.1 39.1 6.5 (3.0-11.9)
1.22 69.6 43.5 6.4 (3.1-11.4)
CI, confidence interval.






Age (per 10 years) <0.001 1.9 1.3-2.8
Gender (female/male) 0.813 0.9 0.4-2.1
Disease duration at vaccination (years) 0.075 1.03 1.0-1.1
DAS28 at vaccination (0–10)* 0.366 1.2 0.8-1.7
HAQ at vaccination (0–3)** 0.332 1.4 0.7-2.6
Diagnosis (RA/SpA) 0.004 4.8 1.7-14.2
Methotrexate at vaccination (yes/no) 0.737 0.9 0.4-2.0
Anti-TNF at vaccination (yes/no) 0.380 1.5 0.6-3.9
Methotrexate + anti-TNF at vaccination (yes/no) 0.428 0.7 0.3-1.7
Prednisolone at vaccination (yes/no) <0.001 7.1 2.7-18.7
Prednisolone at vaccination (mg/day) <0.001 1.2 1.1-1.3
Smoking at vaccination (yes/no) 0.289 1.7 0.7-4.2
Multivariate analysis
Age (years) 0.034 1.5 1.0-2.2
#Diagnosis (RA/SpA) 0.064 2.9 0.9-9.4
Prednisolone at vaccination (yes/no) <0.001 5.6 2.1-15.1
Prednisolone dose (mg/day) <0.001 1.2 1.1-1.3
*DAS28, disease activity score using 28 joint counts; **HAQ, health assessment
questionnaire; #diagnosis (RA/Spa), prednisolone at vaccination (yes/no) and
prednisolone dose (mg/day) are analysed in different regression models
adjusted for age. CI, confidence interval; RA, rheumatoid arthritis; SpA,
spondylarthropathy; anti-TNF, anti-tumour necrosis factor.
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further research.
Using ROC, we identified post-vaccination antibody
levels, which we consider to have sufficiently high speci-
ficity but not too low sensitivity to be protective against
infections. Interestingly, these levels were rather close to
levels of 1 mg/L extrapolated from previous studies in-
vestigating antibody response after Hib vaccination using
polysaccharide vaccine in children and which have sub-
sequently been generally accepted [14,15,17]. Antibody
response and protective levels after vaccination with
more immunogenic conjugate vaccine are not estab-
lished in adults and may differ between different sero-
types. However, we previously reported similar antibody
levels after vaccination with PPV or PVC in patients
with RA receiving MTX, anti-TNF or combination of
these treatments [23].
In all patients post-vaccination antibody levels in-
creased significantly, although patients experiencing ser-
ious infections overall had lower levels compared to
patients without serious infections.Patients with a history of serious pneumococcal infec-
tion within 4 years before vaccination had somewhat
lower pre-vaccination antibody levels than patients with-
out such infections although the difference was not sta-
tistically significant. Pre-vaccination antibody levels
reflect the antibodies naturally acquired in response to
infections and would be expected to be higher in pa-
tients who had such infections. Most infections (13 of
18) occurred in RA patients receiving immunosuppres-
sive treatment (MTX, anti-TNF or combination of these)
when blood samples were taken (immediately before
vaccination). These remedies could have diminished pre-
existing antibody levels, which is in line with our previ-
ous study where both MTX anti-TNF were associated
with low persistence of protective immunity 1.5 years
after pneumococcal vaccination in RA [24]. Unfortu-
nately, no control group was included in the study and
we were unable to measure antibody levels in the non-
vaccinated epidemiologically matched control population
and, therefore, could not estimate the impact of im-
munosuppression on these levels.
As expected, older patients and those with RA had
more serious infections after vaccination but only age
remained a significant predictor after adjustment for
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prednisolone remained a strong predictor after adjust-
ment for age. This is in agreement with previous reports
on association between increasing age and prednisolone
treatment and infections in RA [25-27]. Interestingly,
higher prednisolone dosage was associated with in-
creased infection risk even with the relatively moderate
prednisolone doses in the current study (max 10 mg/
day). One of our inclusion criteria was unchanged doses
of anti-rheumatic drugs (including prednisolone) for at
least 4 weeks before study entry [20]. This criterion pos-
sibly/probably reflects a group of patients in need of an
overall larger long-term prednisolone exposure. The asso-
ciation between low/moderate prednisolone doses >1
month and increased risk of serious infections support the
latest European League Against Rheumatism (EULAR)
guidelines for the management of new-onset RA recom-
mending the tapering of prednisolone as fast as clinically
feasible [26]. Treatment with MTX, anti-TNF or both
combined did not contribute to risk of serious pneumo-
coccal infections in accordance with other reports [25,27].
Compared to RA, fewer SpA patients experienced serious
infections before and also after vaccination. SpA patients as
a group were younger and one-third was treated with anal-
gesics/NDSAIDs without any DMARDs, which is a prob-
able explanation for the difference. This is supported by the
disappearance of the difference between RA and SpA after
adjustment for age in the multivariate analysis.
The present study has important limitations. Usually,
two serological methods are used to estimate the protect-
ive antibody levels: standard ELISA measuring antibody
concentrations and opsonophagocytic assays measuring
the functionality of the antibodies. Unfortunately, the
opsonophagocytic assay was not available at our labora-
tory. On the other hand, a fair correlation between anti-
body concentrations and their opsonophagocytic capacity
has been shown (r between 0.72 and 0.91) [16,28].
Infections were identified from the healthcare register
using ICD-10 diagnostic codes for known putative pneu-
mococcal infections. However, when medical records of
patients diagnosed with putative serious pneumococcal in-
fections were scrutinised, we found that the vast majority
of these infections (83% of serious infections before and
89% after vaccination) were based on X-ray findings or la-
boratory tests. This supports the bacterial origin of the in-
fections but does not prove that infections were caused by
pneumococci. On the other hand, Streptococcus pneumo-
niae is known to be the most common cause of
community-acquired pneumonia in adults [29]. Serotypes
included in the 7-valent conjugate vaccine are shown to
account for 50 to 65% of invasive pneumococcal diseases
in adults >50 years of age [29,30]. Furthermore, we com-
pared the numbers of infections before and after an inter-
vention in the same cohort using the same diagnosticcodes and thus the proportion of potentially misclassified
events is expected to affect pre- and post-vaccination in a
similar way.
In the present study, we chose to measure antibody re-
sponse to only two of seven different serotypes (6B and 23)
presented in the vaccine. These serotypes are included in
both PPV and pneumococcal conjugate vaccines currently
available on the market and have been reported to be asso-
ciated with severe infections and serious clinical outcome
among adults [31]. Although the putative protective levels
probably differ between the serotypes, we assume that im-
munosuppressive treatments would influence the antibody
response to all serotypes in the same manner.
Another weakness is that the number of events was lim-
ited, which precluded analysis of disease and treatment
characteristics or co-morbidities on the occurrence of in-
fections. In addition, when the study was initiated we did
not have the possibility to include a control group of pa-
tients or healthy controls. In spite of these limitations, the
present study is the first to report on the association be-
tween antibody response and protection against infections
after immunisation with pneumococcal conjugate vaccine
in adult immunosuppressed patients with arthritis. Fur-
thermore, we confirmed that putative protective antibody
levels used for healthy adults are applicable for arthritis
patients receiving modern anti-rheumatic treatments in-
cluding MTX, anti-TNF remedies and their combination.
The vast majority of serious infections occurred in pa-
tients receiving immunosuppressive treatment. We have
reported diminished antibody response in RA patients
from this cohort treated with MTX and to a lesser extent
in arthritis patients on anti-TNF [11]. We also recently
demonstrated that these patients had limited protection
against serious infections after pneumococcal vaccination
[13]. In order to induce better antibody response and thus
better protection against infections these findings indicate
that pneumococcal vaccination should preferably be given
before the initiation of immunosuppressive treatment. As
shown by Desai et al. measuring pneumococcal vaccin-
ation rates in a rheumatology practice and improving
those rates is important for encouraging rheumatologists
to vaccinate their patients before starting immunosuppres-
sive treatment [32,33].
Conclusions
In summary, measurement of antibody response after
immunisation with a single dose of pneumococcal con-
jugate vaccine using standard ELISA is a feasible
method for estimating protection induced by vaccin-
ation. Approximately a month after immunisation, anti-
body levels ≥1.01 to 1.29 mg/L against serotypes
included in the vaccine are associated with protection
against severe putative pneumococcal infections in patients
with arthritis treated by modern anti-rheumatic treatments.
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